We provide you with the best medicine purchasing service

Quickly morph client-centric results through performance based applications. Proactively facilitate professional human capital for cutting-edge.

Download Now

5 - 35 mg/kg/day in 4 divided doses. Blood concentration can be monitored; the therapeutic level is not defined, but should be greater than zero (0) and lower than 100 nmol/L (55-59).

PO

Dizziness, Somnolence, fatigue

4

55. Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S, Salomons GS. Creatine Deficiency Syndromes. 1993 doi: NBK3794 [bookaccession][published Online First: Epub Date]|.

56. Belldina EB, Huang MY, Schneider JA, Brundage RC, Tracy TS. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. British journal of clinical pharmacology 2003;56(5):520-5

57. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med 2002;347(2):111-21 doi: 10.1056/NEJMra020552[published Online First: Epub Date]|.

58. Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert opinion on pharmacotherapy 2004;5(11):2255-62 doi: 10.1517/14656566.5.11.2255[published Online First: Epub Date]|.

59. Kaiser-Kupfer MI, Gazzo MA, Datiles MB, Caruso RC, Kuehl EM, Gahl WA. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Archives of ophthalmology 1990;108(5):689-93